Wegovy vs Zepbound (2026): Which Is Better for Weight Loss?

If you've started researching GLP-1 weight-loss drugs, you've hit the same fork everyone hits: Wegovy or Zepbound? They're the two big branded injections, they're advertised everywhere, and the internet is full of confident, contradictory answers. One article says they're basically the same; the next says one is dramatically better; a third buries the one trial that actually compared them under a pile of cross-trial guesswork. The honest picture is more useful than any of those, and it's knowable, because unlike most drug rivalries, these two were put in the same trial against each other.

This guide is built around that evidence. We'll start with the one head-to-head study, because it settles the "which loses more weight" question more cleanly than anything else can, then widen out to the things the trial didn't measure and that often matter more in real life: how each drug feels to take, what each actually costs in 2026, how coverage works, who each one suits, and how to get a legitimate prescription online without overpaying or getting burned. Where a number comes from a trial or a regulator, we cite it, because on a decision this expensive and this personal, vague reassurance is worse than useless.

A note on scope before we dive in. This is a comparison of the two branded, FDA-approved injections — Wegovy (semaglutide) and Zepbound (tirzepatide) — and the real-world routes to getting them, including the cheaper compounded alternatives that many online programs sell. It is not a prescription, a diagnosis, or a substitute for a clinician. These are serious medications with real risks as well as real benefits, and the single most important decision isn't Wegovy-versus-Zepbound at all — it's doing this with a genuine prescriber who takes a real history, not a checkout questionnaire. With that said, let's get into what actually separates the two.

The quick verdict: Wegovy vs Zepbound at a glance

If you read nothing else, read this. The table below is the honest one-screen summary; every row is unpacked, with sources, further down.

Weight-loss figures are from the SURMOUNT-5 head-to-head trial (NEJM 2025). Prices are a 2026 self-pay snapshot from the manufacturers' official pages and change often — always confirm the current number before you commit.

Three things to take from that table. First, on the one measure people most want answered — how much weight will I lose — Zepbound has the better average, and it's not a rounding error. Second, "better average" sits next to several columns where Wegovy is even or ahead, most notably the cardiovascular outcome data and its longer real-world history. Third, almost none of this matters if your insurance covers one and not the other, or if one is simply out of budget — which is why the cost and coverage sections below are not an afterthought. The rest of this guide turns each of these rows into something you can actually decide on.

What Wegovy and Zepbound actually are

Start with the basics, because a lot of confusion comes from mixing up brand names and molecules. Wegovy is Novo Nordisk's brand name for semaglutide dosed for weight loss. Zepbound is Eli Lilly's brand name for tirzepatide dosed for weight loss. Same molecules you've heard of under other names: semaglutide is also sold as Ozempic (for type 2 diabetes) and as an oral pill; tirzepatide is also sold as Mounjaro (for diabetes). When people argue "Ozempic vs Mounjaro," they're really arguing semaglutide vs tirzepatide — the same contest as Wegovy vs Zepbound, just under the diabetes labels.

Both drugs belong to a class called incretin mimics — they copy gut hormones your body releases after you eat. Those hormones do several things that add up to eating less without white-knuckle willpower: they slow how fast your stomach empties (so you feel full longer), they act on appetite centers in the brain (so you're less hungry and less preoccupied with food), and they improve how your body handles blood sugar and insulin. The Harvard Health overview walks through the underlying biology in plain terms. The National Institutes of Health's NIDDK lists both among the prescription medications approved to treat obesity.

Here's the one mechanistic difference that explains most of the rest of this guide. Wegovy (semaglutide) targets one receptor: GLP-1. Zepbound (tirzepatide) targets two: GLP-1 and GIP. Tirzepatide is a "dual agonist" — it mimics a second gut hormone, GIP, on top of the GLP-1 action semaglutide has. The leading explanation for why Zepbound tends to produce more weight loss is exactly this: it's pulling two metabolic levers instead of one. That's a simplification — the biology of GIP in obesity is genuinely complicated and still being worked out — but as a mental model, "one hormone vs two" is the right starting intuition for why the trials shook out the way they did.

Both are FDA-approved specifically for chronic weight management, which matters more than it sounds. Approval means each went through large trials for this exact use and carries an approved label, a known dosing schedule, manufacturer quality control, and a defined safety profile. Wegovy was approved for weight management in 2021; Zepbound followed with its own weight-management approval in 2023. You can read the plain-language drug information for each at MedlinePlus — semaglutide and tirzepatide. Keep that approved-for-this-use status in mind, because it's the single biggest thing separating these two brands from the compounded versions many online programs sell cheaply — a distinction we return to in detail later.

Both are, in their primary form, once-weekly injections you give yourself with a pre-filled pen or a vial and syringe, in the fat just under the skin of the belly, thigh, or upper arm. The needles are short and fine; most people describe the shot as a minor pinch, and the weekly rhythm is easy to build a habit around. There's one important wrinkle to the "injection" framing: semaglutide now also comes as an oral pill (the Wegovy pill, a 25 mg tablet approved in late 2025), which changes the convenience calculus for people who dread needles. We cover the pill where it's relevant below and in depth in our dedicated GLP-1 weight-loss pill guide; for the core Wegovy-vs-Zepbound comparison, though, we're talking about the two injections, since that's what the head-to-head trial tested and what most people start on.

One last bit of grounding: these are not interchangeable with "Ozempic for weight loss" in a regulatory sense, even though the molecule is the same. Wegovy and Zepbound are the versions dosed and labeled for weight management; prescribing a diabetes brand for weight loss is an off-label decision. For the purposes of this guide — choosing a weight-loss treatment and getting it legitimately — Wegovy and Zepbound are the on-label options, and that's what we compare.

Wegovy, Ozempic, Zepbound, Mounjaro: untangling the brand maze

One reason this comparison confuses people is that the same two molecules are sold under four big brand names, and the marketing rarely makes the relationships clear. Sorting them out takes two minutes and prevents real mistakes, like assuming "Ozempic for weight loss" is a different drug from Wegovy, or that Mounjaro and Zepbound are rivals when they're the same thing.

Here's the whole map. Semaglutide is sold as Wegovy (approved for weight loss), Ozempic (approved for type 2 diabetes), and as an oral pill (a 25 mg tablet for weight loss). Tirzepatide is sold as Zepbound (approved for weight loss) and Mounjaro (approved for type 2 diabetes). So the "Wegovy vs Zepbound" question is identical in substance to "semaglutide vs tirzepatide," and also to "Ozempic vs Mounjaro" — just with the weight-loss labels instead of the diabetes labels. When a headline pits Ozempic against Mounjaro, it's the exact same molecular contest this guide is about.

Why does this matter beyond trivia? Three reasons. First, coverage and pricing can differ by brand even for the same molecule: a plan may cover Ozempic (diabetes) but not Wegovy (weight loss), which is why people sometimes end up with the "diabetes" brand prescribed off-label — a decision for a clinician, and one with its own insurance implications. Second, the weight-loss brands (Wegovy, Zepbound) are dosed and labeled specifically for weight management, which is the on-label, intended use for this purpose; the diabetes brands are optimized for blood-sugar control. Third, compounded products add yet another layer — they're sold as "compounded semaglutide" or "compounded tirzepatide," i.e., by molecule, not brand, because they're not the branded product at all. Our deep dive on tirzepatide vs semaglutide compares the molecules directly if you want the science without the brand labels.

The practical takeaway: when you research or talk to a prescriber, think in molecules first, brands second. Decide whether semaglutide or tirzepatide fits you better (using everything in this guide), then sort out which brand, label, or compounded version is the right way to actually get that molecule given your coverage and budget. People who shop by brand name alone end up comparing the same drug to itself, or missing that the "cheaper" option two tabs over is the identical molecule under a different label.

The head-to-head trial: SURMOUNT-5

Almost every "X vs Y" drug comparison online is really a cross-trial comparison — someone takes the weight-loss number from one drug's study and the number from a different drug's study and lines them up. That's genuinely unreliable, because the two trials enrolled different people, ran for different lengths, used different diet-and-exercise backdrops, and measured things slightly differently. The gold standard is a trial that gives the same people one drug or the other and compares them directly. For Wegovy vs Zepbound, that trial exists, and it's the most important single piece of evidence in this entire guide.

It's called SURMOUNT-5, and it was published in the New England Journal of Medicine in 2025 (Aronne et al., NEJM 2025). Here's the design in plain terms: 751 adults with obesity but without diabetes were randomly assigned to take either tirzepatide (Zepbound) or semaglutide (Wegovy), each pushed to the maximum dose the person could tolerate, for 72 weeks — about 16 months. Both groups were titrated up the normal way and supported with lifestyle guidance. Then the researchers measured who lost more weight. Because it's randomized and head-to-head, it sidesteps the apples-to-oranges problem that plagues every cross-trial claim.

The result was clear: Zepbound produced more weight loss than Wegovy. On average, the tirzepatide group lost about 20.2% of their body weight, versus about 13.7% in the semaglutide group. In absolute terms that's roughly a 22.8 kg (about 50 lb) average loss on Zepbound versus about 15.0 kg (about 33 lb) on Wegovy — a gap of around 6.5 percentage points of body weight, or stated as a relative figure the way the headlines did, roughly 47% more mean weight loss on tirzepatide. The trial also tracked waist circumference, where tirzepatide again came out further ahead. By the measure most people care about, this is as close to a definitive answer as drug research gives you: on average, Zepbound takes off more.

Source: SURMOUNT-5, NEJM 2025. Doses were each drug's maximum tolerated level (tirzepatide 10 or 15 mg; semaglutide 1.7 or 2.4 mg). The trial was open-label.

Now the honest caveats, because they matter and because a trial is only as good as its fine print. SURMOUNT-5 was open-label — participants knew which drug they were on — which is a real limitation, though for an objective outcome like weight it's a modest one. It enrolled people without diabetes, so it doesn't directly speak to people with type 2 diabetes, in whom GLP-1 weight responses tend to run lower. It's a single trial; one study, however well run, is one study. And crucially, it compared the drugs at the doses that existed when it was designed — which, as we'll see in a moment, is about to be complicated by a new, higher Wegovy dose that wasn't in this trial. None of these caveats erase the result. They right-size it: a clear average advantage for Zepbound, from one strong randomized trial, in people without diabetes, at the then-standard doses.

It's also worth being clear about why a single trial carries this much weight, since "one study" is sometimes used to wave results away. SURMOUNT-5 is persuasive not because one study is ever the last word, but because it's the right design for this exact question — randomized, head-to-head, adequately sized, long enough to capture the full weight-loss arc, and pointing in the same direction as each drug's separate pivotal trial. When a direct comparison and both drugs' individual trials all agree that tirzepatide loses more, that's a consistent body of evidence, not a lone outlier. The appropriate humility is about the size of the gap in any given person and about the populations not studied — not about the direction, which is about as settled as this kind of question gets.

The most important thing SURMOUNT-5 does is retire the lazy claim that "they're basically the same." On average, they're not — Zepbound loses more. But the trial measures an average, and the single biggest mistake people make with this number is treating it as a personal prediction. Averages hide enormous spread: in these trials, some people on Wegovy lost more than the average Zepbound user, and some people on Zepbound lost little. Which brings us to the part the head-to-head number can't tell you — how much you might lose, and everything else that goes into the choice.

Weight loss: how much on each, realistically

The head-to-head number answers "which loses more on average." It does not answer "how much will I lose," and conflating the two is the source of a lot of disappointment and a lot of overspending. Let's build the realistic picture, using each drug's own pivotal trial alongside the head-to-head.

For Wegovy (semaglutide 2.4 mg), the landmark trial was STEP 1 (NEJM 2021), where adults with obesity lost on average about 14.9% of body weight over 68 weeks. For Zepbound (tirzepatide), the pivotal trial was SURMOUNT-1 (NEJM 2022), where the highest dose produced an average of roughly 21% of body weight lost over 72 weeks. Those two trials, plus the head-to-head, all point the same direction: Wegovy tends to land in the mid-teens percentage-wise, Zepbound in the high-teens to around 20%. Our dedicated breakdown of how much weight you can realistically lose on a GLP-1 digs into the distribution behind these averages.

But averages are the least useful number for an individual. Here's what the spread actually looks like, and it's the part the ads skip. In these trials, weight loss ranged from people who lost almost nothing to people who lost 30% or more. Roughly speaking, on semaglutide about a third of people lost 15% or more of their weight; on tirzepatide, a substantially larger share hit that mark, and a meaningful minority lost 25% or more. The takeaway isn't a single number to expect — it's a range to plan for, with the odds of a big result better on Zepbound but a genuinely good result very achievable on either. Two people on the same drug at the same dose can have completely different outcomes, driven by biology no questionnaire can predict in advance.

Then there's the twist that complicates the clean "Zepbound wins" story: the new, higher-dose Wegovy. In 2026 the FDA approved Wegovy HD, a 7.2 mg semaglutide dose (Novo Nordisk, 2026), above the previous 2.4 mg ceiling. In its trial program, the higher dose pushed average weight loss up toward roughly 18–21% depending on how it's measured — meaningfully more than the 2.4 mg dose that lost to Zepbound in SURMOUNT-5. The honest framing: this narrows the gap, and may close much of it for some people — but the head-to-head trial used the old 2.4 mg dose, so there is no direct comparison of Zepbound against 7.2 mg Wegovy yet. Anyone telling you the new dose definitively ties or beats Zepbound is guessing ahead of the evidence. What we can say: the higher dose makes Wegovy a stronger contender than the 13.7% head-to-head figure alone suggests, at the cost of more side effects at the top dose.

Two realities sit underneath all of these numbers and matter more than which drug you pick. First, the weight loss is dose-dependent and titration-dependent — people who rush the dose or never reach an effective one get less, and people who can't tolerate the top dose land lower than the trial average regardless of brand. Second, and this is the one nobody wants to hear, the results depend on staying on the drug. These are treatments for a chronic condition, not a course of antibiotics; when people stop, weight tends to come back. In the semaglutide withdrawal data, people regained a large share of what they'd lost within about a year of stopping — our guide on what happens when you stop a GLP-1 covers this in full. Whichever brand loses you the most weight is the wrong question if you can't afford or sustain it long-term; the drug you can actually stay on usually beats the drug with the better trial average you quit in month four.

It helps to think in responder tiers rather than a single average, because that's how the results actually distribute. Roughly: a minority of people are "super-responders" who lose 25% or more and are often astonished by the result; a large middle group lands in the clinically meaningful 10–20% range that improves health markers substantially; a smaller group gets a modest 5–10%; and a minority are "low responders" who, despite doing everything right, lose relatively little. Zepbound shifts more people up into the higher tiers than Wegovy does, which is what the better average reflects — but every tier contains users of both drugs. The uncomfortable truth no program advertises is that you won't know your tier until you try, because the biology that determines it isn't something a questionnaire can read in advance. This is also why a fair trial matters: writing a drug off before a maintenance dose risks mislabeling yourself a low responder when you simply hadn't reached an effective dose yet.

So, realistically: expect a range, not a guarantee; tilt the odds of a larger result toward Zepbound, especially against standard-dose Wegovy; give whichever drug you choose a real titration and several months before judging it; and weigh the trial averages against the far more decision-relevant question of which one you can sustain. The "best" weight-loss drug is the one that produces a good-enough result you can keep.

Side effects: how the two compare

Weight loss is only half the ledger. The other half — the one that actually drives most people's day-to-day experience and a lot of the quitting — is side effects. The good news is that the two drugs have broadly similar side-effect profiles, because they work through overlapping mechanisms. The nuances between them are real but smaller than the marketing on either side implies.

For both drugs, the side effects are overwhelmingly gastrointestinal: nausea, constipation, diarrhea, vomiting, and reflux or that "food is just sitting there" fullness. They come from the same place for both — the drugs slow your stomach — and they follow the same pattern for both: worst when you start and each time you step up the dose, then fading as your body adapts. In the pivotal trials, nausea was the most common complaint, affecting a large share of people on semaglutide and a somewhat smaller share on tirzepatide, with the other GI effects trailing behind. Our full GLP-1 side-effects guide breaks down each one and exactly how to manage it; the short version is that these are common, usually mild-to-moderate, and largely controllable with slow titration and simple food-and-timing habits.

Does one drug cause fewer side effects? This is where the head-to-head trial is quietly illuminating. Despite producing more weight loss, Zepbound in SURMOUNT-5 had a lower rate of people stopping over GI side effects — about 2.7% discontinued for that reason on tirzepatide versus about 5.6% on semaglutide. That's a useful data point against the intuition that "stronger drug = rougher ride." It doesn't mean Zepbound is side-effect-free or gentle for everyone — plenty of people get nausea on it — but at least in that trial, the more effective drug was also the one fewer people quit over. Tolerance is deeply individual, though: some people breeze through semaglutide and struggle on tirzepatide, and the only way to know your own response is to try, under supervision, with a careful titration.

*Approximate rates from each drug's pivotal trial (STEP 1, NEJM 2021; SURMOUNT-1, NEJM 2022), plus head-to-head discontinuation from SURMOUNT-5. Cross-trial rates aren't perfectly comparable; tirzepatide figures are dose-dependent.

Beyond the common GI stuff, both drugs share the same tier of rarer but serious risks, and they're the reason these belong with a real prescriber rather than a checkout form. Both carry a boxed warning about thyroid C-cell tumors (based on rodent studies) and are not for people with a personal or family history of medullary thyroid carcinoma or MEN 2. Both can raise the risk of gallbladder problems (rapid weight loss does this independently) and, rarely, pancreatitis. Both can cause low blood sugar when combined with certain diabetes medications like insulin or sulfonylureas. These risks are uncommon, but they're real, they're class-wide, and they don't meaningfully separate the two drugs — which is exactly why "which has fewer side effects" is less decisive than people expect. The serious-risk column is essentially a tie; the common-GI column slightly favors Zepbound on the head-to-head dropout data.

A practical note that applies to both: a large majority of the side-effect difference you'll actually experience comes down to how carefully the dose is titrated and how you eat, not which brand is on the pen. Rushing the dose to lose weight faster is the single most common self-inflicted cause of a miserable first month, on either drug. Smaller, lower-fat meals; eating slowly; stopping before you're full; staying hydrated; and giving each dose step a couple of weeks to settle — these blunt the side effects of Wegovy and Zepbound alike. The brand matters less than the ramp.

Managing side effects: the practical playbook (works for both)

Because the side-effect profiles are so similar, the management strategy is essentially the same for Wegovy and Zepbound — and getting it right is what separates people who stay on the drug and succeed from people who quit in a rough week two. Side effects are the number-one reason people stop a GLP-1, and the vast majority of that is preventable or manageable. Here's the playbook; our full side-effects guide goes deeper on each item.

Respect the titration — this is 80% of it. Nearly every bad first month traces to a dose raised too fast. The starter doses exist to let your stomach adapt; moving up before you've settled, or pushing to a higher dose to lose weight faster, is the single most common self-inflicted mistake on either drug. If a dose step brings side effects you can't comfortably manage, the fix is usually to hold at that dose longer, or step back down temporarily, not to power through — a conversation to have with your prescriber, who can slow the ramp without derailing your progress.

Eat for a stomach that's running slow. Almost every GI side effect comes from the drugs slowing your stomach, so the food strategy follows one rule: don't overload it. In practice that means smaller meals (your old portions are now often too much), lower-fat choices (fat slows emptying further and worsens nausea), eating slowly, and stopping before you feel full — because the gap between "satisfied" and "queasy" narrows on these drugs. Bland, simple foods sit better on rough days; greasy, heavy, or very large meals are the fastest route to nausea. None of this is deprivation; it's matching intake to a stomach that now holds and processes less at a time.

Stay ahead of constipation and hydration. Because you're eating and drinking less, constipation is common on both drugs. Fluids, fiber, movement, and sometimes an OTC stool softener or fiber supplement (cleared with your clinician) keep it from becoming a problem. Dehydration sneaks up when appetite is suppressed — you simply forget to drink — and it worsens both constipation and that generally-unwell feeling, so deliberate hydration is one of the highest-value habits on either drug.

Time the dose to your life. Some people find taking the weekly shot before a lighter-activity day, or in the evening, helps them ride out any transient nausea; others prefer mornings. There's no universal best day — the point is you can choose the timing that fits your week, and keep it consistent. And give each new dose a couple of weeks: the predictable pattern on both drugs is that side effects peak after a dose change and then ease as your body adapts, so an uncomfortable few days after stepping up is usually a phase, not a verdict.

Know the line between uncomfortable and dangerous. The playbook above handles ordinary GI discomfort, which is the overwhelming majority of what people experience. But certain symptoms mean stop-and-call rather than manage-and-continue: severe, persistent abdominal pain (especially radiating to the back), relentless vomiting or inability to keep fluids down, signs of a gallbladder attack, or any symptom that feels clearly out of the ordinary. These are uncommon, they don't meaningfully differ between the two drugs, and they're exactly why a real prescriber — not a questionnaire — belongs in this process. "Tough it out" is the right instinct for nausea and the wrong instinct for a red flag.

Muscle loss and body composition

One concern now comes up with both drugs more than almost any other, and it deserves a straight answer: are you losing muscle along with fat? The honest reply is yes, to a degree — and it's a shared trait of rapid weight loss generally, not a quirk of one brand over the other. Understanding it changes how you should eat and move while on either drug.

When anyone loses weight quickly — by any method, drug or not — a portion of the loss is lean mass (muscle and other non-fat tissue), not just fat. GLP-1 drugs produce large, relatively fast weight loss, so some lean-mass loss comes with the territory; studies of these drugs have measured a meaningful fraction of total loss as lean tissue. This isn't unique to Wegovy or Zepbound, and it isn't a reason to avoid them — but it is a reason to be deliberate, because preserving muscle protects your metabolism, your strength, and your long-term results. The concern is real; the panic some headlines attach to it is not.

The two levers that protect lean mass are well established and entirely in your control: adequate protein and resistance training. Eating enough protein (often harder on these drugs precisely because your appetite is suppressed, so it takes intention) gives your body the raw material to hold onto muscle, and strength training signals your body to keep it. People who lose weight on a GLP-1 while hitting their protein and lifting tend to lose a much healthier ratio of fat to muscle than people who just eat less of everything and skip the gym. This is the single most actionable thing in the body-composition conversation, and it applies identically to Wegovy and Zepbound.

Does the brand matter here? Not in a way that should drive your choice. Both drugs cause the same general pattern — large weight loss with some lean-mass component — and there's no strong evidence that one is meaningfully better than the other for preserving muscle at matched weight loss. Since Zepbound tends to produce more total weight loss, it may produce more absolute lean-mass loss simply because the overall loss is larger, but the proportion and the solution (protein + resistance training) are the same. Choosing between them on muscle grounds isn't well supported; choosing to train and eat protein whichever you take is.

There's also an encouraging side worth stating, because the muscle conversation can tip into fear. The weight loss these drugs produce improves many health markers that matter more than a body-composition scan — and for people with obesity, the metabolic and cardiovascular benefits of losing substantial weight are large and well documented (semaglutide's cardiovascular-outcome data is a case in point). The goal isn't to avoid all lean-mass change — that's unrealistic with meaningful weight loss — it's to minimize it with protein and strength work while you capture the broader benefits. Done that way, body composition is a thing you manage, not a reason to hesitate, on either drug.

Who shouldn't take Wegovy or Zepbound

These drugs are not for everyone, and the exclusions are essentially the same for both — another reason the choice between them is less about safety screening and more about fit. This is general information, not a substitute for a clinician's assessment, which is exactly the point: deciding whether a GLP-1 is safe for you is a medical judgment that requires a real history, which is why a legitimate program always includes a genuine prescriber.

Both Wegovy and Zepbound carry a boxed warning about thyroid C-cell tumors (based on rodent studies), so neither is used in people with a personal or family history of medullary thyroid carcinoma or the genetic syndrome MEN 2. Both are generally avoided in people with a history of pancreatitis or certain serious gallbladder disease, used cautiously (or not at all) in pregnancy and breastfeeding — these drugs are not for weight loss during pregnancy — and require care in people with a history of severe gastrointestinal disease like gastroparesis. People taking insulin or sulfonylureas for diabetes need dose adjustments because of hypoglycemia risk. The authoritative drug-information pages at MedlinePlus (semaglutide, tirzepatide) list the warnings in full, and the NIH's NIDDK overview covers who these medications are and aren't for.

There's also an eligibility dimension separate from safety: these drugs are approved for specific populations — generally adults with obesity (a BMI at or above 30), or overweight (BMI at or above 27) with a weight-related condition like high blood pressure, high cholesterol, or type 2 diabetes. They are not approved or appropriate as a cosmetic shortcut for someone at a healthy weight, and a responsible prescriber will not hand them out on that basis. This matters for the online route specifically: a program that prescribes without establishing that you actually meet the medical criteria is a red flag, not a convenience.

The reason this belongs in a Wegovy-vs-Zepbound guide is to underline the single most important decision again: because the contraindications, warnings, and eligibility criteria are nearly identical between the two drugs, they don't help you pick between them — but they absolutely determine whether you should be on either, and that's a clinician's call. If a program lets you check a few boxes and buy a GLP-1 without any real evaluation of your history, the problem isn't which drug you chose; it's that no one with the training to catch a contraindication was ever in the loop. Choose a program where a licensed clinician actually evaluates you. That protects you more than any difference between the two molecules.

Dosing, titration, and how you take each one

Both drugs follow the same core logic: start at a low, barely-effective dose and step up over months to the dose that actually drives weight loss. This isn't bureaucratic caution — it's the entire tolerability strategy. The slow ramp lets your stomach adapt so that by the time you reach the stronger doses, the side effects are manageable. People who try to skip steps almost always pay in nausea, and often quit.

Wegovy (semaglutide) uses a roughly monthly step-up through a fixed ladder of doses — commonly described as 0.25 mg, then 0.5, 1.0, 1.7, and 2.4 mg once weekly — with each step held for about four weeks before moving up, reaching the 2.4 mg maintenance dose at around month five. The new 7.2 mg high dose sits above that, intended for people who've already tolerated 2.4 mg and want additional weight loss, at the cost of more GI side effects. Zepbound (tirzepatide) uses its own ladder — commonly 2.5 mg to start, then 5, 7.5, 10, 12.5, and up to 15 mg — again stepping roughly monthly, with several possible maintenance doses depending on how much help you need and tolerate. The exact schedule your clinician uses may differ; both labels build in flexibility to slow down or hold a dose if side effects flare.

The practical upshot of the two ladders is similar: budget on the order of four to five months to reach a full maintenance dose, and don't judge the drug's effectiveness until you're there and have given it time. A common and costly misread is quitting at week six on a starter dose because "it's not working much" — of course it isn't; the starter dose is designed mainly to build tolerance, not to melt weight. The weight loss accelerates as you climb. This is identical in spirit for both brands.

On the how-you-take-it mechanics, they're alike: a once-weekly subcutaneous injection you do yourself, same day each week, rotating sites on the belly, thigh, or upper arm. Wegovy has historically used a single-use pre-filled pen; Zepbound comes as both single-dose pens and vials (the vials being part of how Lilly offers lower self-pay pricing). Both need refrigeration within their labeling, both use short fine needles, and both become a quick, unremarkable weekly habit for most people within a shot or two.

The one genuine fork in the "how you take it" question is semaglutide's oral option. The Wegovy pill (a 25 mg tablet, approved in late 2025 — Novo Nordisk, 2025) gives semaglutide a needle-free route, with its own particular rules (taken on an empty stomach with a small sip of water, then waiting before eating or drinking). Zepbound has no oral form. So if needle avoidance is a dealbreaker, the comparison tilts: a semaglutide pill exists, a tirzepatide pill (as Zepbound) does not. The oral pill's weight-loss results and the trade-offs against the injections are their own topic — see our weight-loss pill guide — but it's worth knowing the option is semaglutide-only when weighing the two brands.

Whichever you choose, the dosing takeaways are the same and worth repeating because they prevent the most common failures: respect the ramp, reach a real maintenance dose, give each step time, and never rush to a higher dose to speed up results. The schedule is the tolerability plan, not an obstacle to it.

What to expect, month by month

Whichever drug you choose, the arc of the first several months is broadly similar, and knowing it prevents the two classic mistakes: quitting too early because "it's not working," and judging the drug before you've reached an effective dose. Here's the realistic timeline for both Wegovy and Zepbound.

Month 1 (starter dose). You begin at a low dose designed mainly to build tolerance, not to drive weight loss. Expect modest appetite changes and, for many people, the first brush with side effects — some nausea, maybe constipation — especially in the first week or two. Weight loss this month is usually small, and that's by design; the starter dose is a ramp, not the destination. The work of month one is establishing the habit and letting your stomach adapt, not hitting a number.

Months 2–4 (stepping up). You climb the dose ladder roughly monthly. This is where appetite suppression becomes noticeable — smaller portions satisfy you, food noise quiets down — and where steady weight loss typically establishes itself. Each dose increase can bring a few days of renewed side effects that then settle, which is the normal pattern on both drugs. This is also the stretch where people who rushed the dose struggle most, and where patience and good food habits pay off. By the end of this window many people are approaching or at a maintenance dose.

Months 4–6 (reaching maintenance). You arrive at a full maintenance dose, and this is where the drug is doing what it was designed to do. Weight loss continues at a meaningful pace for most people, and the side effects that were sharpest during titration have usually eased as your body adapted. This is the earliest point at which it's fair to judge how well the drug is working for you — judging at month two, on a starter dose, is like rating a car by how it idles. If results are disappointing at a tolerated maintenance dose after a fair trial, that's the moment to discuss options with your prescriber, including a switch.

Months 6–12 and beyond. Weight loss typically continues but gradually slows as you approach a new set point; the big trials ran to around 68–72 weeks for a reason — that's roughly how long the major loss unfolds. Many people reach a plateau in the second half of the first year, which is normal and not a failure. The central question shifts from "how fast am I losing" to "how do I sustain this" — because, as covered above, stopping tends to bring weight back. This is where the chronic-treatment framing becomes concrete: the plan is ongoing, and the drug you can afford and tolerate long-term beats the one with the better trial average that you quit. Our guide on realistic results by the numbers and the first-four-weeks guide go deeper on the early and long arcs.

The single most useful thing to internalize from this timeline: effectiveness reveals itself at maintenance dose, months into treatment — not in the first few weeks. Both drugs are slow-burn by design. Expecting dramatic early loss sets you up to quit a drug that was about to work; expecting the real results at months four through twelve sets you up to actually get them. That patience applies equally to Wegovy and Zepbound, and it's worth more than picking the "right" one.

Cost compared: what Wegovy and Zepbound really run in 2026

For a lot of people this section decides the whole thing, because the "better" drug you can't afford isn't better for you. Pricing on these drugs moves constantly — manufacturer promotions, insurance quirks, and new self-pay programs change the math every few months — so treat every number here as a 2026 snapshot to verify, not a quote. We keep our live, cross-provider pricing current in the GLP-1 cost guide and on the main comparison. Here's how the money works.

With commercial insurance that covers weight-loss drugs. This is the cheapest path when it's available. Manufacturer savings cards can bring either Wegovy or Zepbound down to roughly $25 a month for people with eligible commercial insurance that covers the drug. The catch is the "covers the drug" part: many employer plans either exclude weight-loss medications entirely or gate them behind requirements (a higher BMI threshold, documented prior attempts, prior authorization). If your plan covers them, a savings card is usually the best deal going, and the Wegovy-vs-Zepbound choice may come down to which one your formulary prefers. Check the official pages — NovoCare for Wegovy and Zepbound's official cost page — for current terms.

Self-pay / cash, buying the brand directly. Both makers now sell direct to patients, which has pulled cash prices down from the old ~$1,000+ list prices. As a 2026 snapshot: Novo Nordisk's direct Wegovy was running around an introductory ~$199 for early fills, then roughly $349/month; Lilly's direct Zepbound (via its single-dose vials) was running roughly $299–$499/month depending on the dose, with the lowest doses cheapest. These numbers shift with promotions and dose, and both have had year-end offers, so the gap between the two brands at cash price is often small and sometimes flips depending on the month and your dose. The reliable move is to price your dose on both official sites the week you're deciding.

Medicare and other coverage. Coverage for weight loss specifically has historically been restrictive, but there are evolving pathways — including a Medicare route that, for eligible beneficiaries, brought certain GLP-1s to around $50/month for a defined window (see the CMS GLP-1 program information). If a GLP-1 is covered for a related condition (type 2 diabetes, or for semaglutide, cardiovascular risk reduction), that can also change the economics. Coverage rules are intricate and change yearly; confirm your own situation with your plan.

Prices change frequently and vary by dose, plan and promotion. Brand figures from the manufacturers' official pages (NovoCare, Zepbound); compounded ranges from the programs we track. Always confirm the current number at checkout.

A few money mechanics worth knowing, because they apply to both brands and quietly save real amounts. HSA and FSA dollars can typically be used for prescribed GLP-1s, which effectively discounts the cost by your tax rate — a meaningful cut on a few-hundred-dollar monthly expense. Watch the prepay trap on compounded programs: the lowest advertised monthly rates often require committing to 6 or 12 months up front, which unlocks the savings but moves the risk onto you if the drug doesn't suit you or a refill runs late — our guide on what to ask before you prepay covers the refund questions to settle first. And ignore the "$39 first month" style teasers when comparing: the number that matters is the ongoing price at your maintenance dose, not the intro hook, because the first-month rate is the single biggest source of surprise-charge complaints. Price your real monthly cost at a maintenance dose, on both the brand and any compounded option, and compare those — not the headline.

The honest summary on cost: if you have commercial coverage, the two brands are often a near-tie at around $25/month, and your formulary may pick for you. If you're paying cash, the brands land in the few-hundred-a-month range, close enough that dose and current promotions matter more than the Wegovy-vs-Zepbound label. And if cash-brand pricing is simply out of reach, that's where the compounded alternatives come in — dramatically cheaper, widely sold online, and carrying real trade-offs we're about to cover honestly. Cost is often the deciding variable, so price your exact situation before you let a trial average make the call.

How to get Wegovy or Zepbound online

Most people now start a GLP-1 through an online program rather than a traditional in-person visit, and for good reason: it's faster, usually cheaper, and the care model fits a medication you manage weekly from home. But "online" spans a wide range, from excellent telehealth clinics with real prescribers to thin questionnaire mills, and the route you choose shapes both what you'll pay and what you'll get. There are essentially two online paths, and they answer different questions.

Path one: get the actual brand (Wegovy or Zepbound) online. A number of legitimate telehealth programs will do a proper intake, connect you with a licensed clinician, prescribe the branded drug, and — importantly — help you navigate insurance and savings cards, which is where a lot of the real savings on brand-name GLP-1s live. This is the route if you specifically want the FDA-approved product, want to use coverage, or simply want the known quantity. Path two: get a lower-cost compounded alternative. Many online programs sell compounded semaglutide or tirzepatide — the same molecules, prepared by a compounding pharmacy rather than the brand manufacturer — at a fraction of the brand price. That route trades the brand's FDA approval and quality guarantees for a much lower monthly cost, and it carries real caveats we cover in the next section.

Here are the programs we rate most highly for getting started — chosen for legitimate clinician-led care, honest pricing, and (for the first two) real help getting the branded drug and using insurance. Our rankings are independent; see how we score and how we make money below.

A few words on choosing between the routes they represent. If your goal is the branded drug with insurance help, a full-service program that carries Wegovy and Zepbound and has an insurance concierge (like the first two above) earns its slightly higher cost by potentially unlocking that ~$25/month covered price and handling the paperwork. If your goal is the lowest reliable monthly cost and you're comfortable with a compounded product from a licensed program, a top-rated compounded service can cost a fraction of brand pricing. Both are legitimate choices; they're just answers to different questions. You can compare the full field — branded and compounded — in our provider reviews and head-to-head comparisons.

If you want a concrete vetting routine before you enter a card number, work through this in order. Confirm there's a real clinician — a licensed prescriber who evaluates your history and can be reached with questions, not just a form that approves everyone. Read the actual ongoing price, at a maintenance dose, not the first-month teaser, and check what happens to the price as your dose rises. Find the cancellation and refund terms before you buy, especially if the cheap rate requires a multi-month prepay — know exactly how you get out and what you're owed if a refill is late or the drug doesn't suit you. Check what's actually being prescribed (branded Wegovy/Zepbound vs compounded, and from what kind of pharmacy). And look for pressure tactics — countdown timers, pushes to prepay a year, "limited stock" urgency — which correlate with the programs you least want. A legitimate service answers all of these cleanly; one that dodges them is telling you something.

Whatever route you pick, the non-negotiables of a legitimate online program are the same, and they're worth more than any price difference. There should be a real medical intake (not just a payment form), a licensed clinician who can answer questions and adjust your plan, transparent pricing that shows the ongoing cost and not just a teaser first month, clear terms for refills and cancellation, and a pharmacy that's properly licensed. Our guide on how to spot a legit online clinic lays out the red flags; if a program skips the medical part or hides the real price, walk away regardless of how cheap the headline looks.

The compounded alternative — and its trade-offs

You can't honestly compare Wegovy and Zepbound in 2026 without addressing the elephant in the room: compounded semaglutide and tirzepatide, sold by many online programs for a fraction of the brand price. For a lot of people, the real decision isn't Wegovy vs Zepbound at all — it's branded vs compounded. Here's the straight version, because this is where misinformation runs thickest in both directions.

Compounded GLP-1s use the same active molecules — semaglutide or tirzepatide — but are mixed by a compounding pharmacy rather than manufactured and FDA-approved as a finished product. That's the crucial distinction: compounded drugs are not FDA-approved, which means they haven't gone through the agency's review for safety, effectiveness, and manufacturing quality the way Wegovy and Zepbound have. The FDA has been explicit about its concerns with unapproved GLP-1 drugs used for weight loss, including dosing errors and quality variability. Compounding is legal and long-established for legitimate needs, and many licensed pharmacies do it carefully — but the quality floor is the pharmacy's, not the FDA's, and that's the trade you're making.

Why do people choose it anyway? Cost, mostly. Where branded cash pricing runs a few hundred dollars a month, compounded programs often run from around $49 to $199 a month, medication included. For people without coverage, that gap is the difference between starting treatment and not. There's also a legitimacy question that shifted recently: compounded GLP-1s surged during the brand shortages, and the rules around them changed as those shortages resolved — a regulatory story we track in detail in is compounded semaglutide still legal. The short version is that the landscape is narrower and more scrutinized than it was at the peak, which makes who you buy from matter more than ever.

So how should you weigh it? Honestly, like this. Branded (Wegovy/Zepbound) buys you FDA approval, manufacturer quality control, a known dose in a known device, and the exact products the trials studied — for more money. Compounded buys you a much lower price and the same core molecule — at the cost of FDA approval and with real variability in pharmacy quality, so vetting the provider is on you. Neither choice is "the scam" and neither is "obviously right." If you can get branded covered by insurance for ~$25/month, that's usually the clear winner. If you're paying cash and brand pricing is out of reach, a carefully vetted compounded program from a licensed clinic is how a lot of people access treatment they otherwise couldn't — with eyes open about the trade-off. Our full breakdown of compounded vs brand-name vs pills walks through exactly what's FDA-approved and what isn't.

One firm line regardless of which you choose: vet the pharmacy and the clinician. The compounded market's quality varies more than the branded market's, so the red flags matter more — no real medical intake, prices too good to be true, no licensed prescriber, vague sourcing, pressure to prepay for many months. The molecule being identical doesn't make every compounded product equivalent; the preparation and the pharmacy are where the risk lives. Choose a program that takes safety seriously, and the compounded route becomes a reasonable, lower-cost path; choose carelessly, and you've taken on the one risk these drugs don't otherwise carry.

Which should you choose? A decision framework

There's no universal winner, which is why "just tell me the best one" gets a frustrating answer. But the decision isn't actually hard once you sort it by what matters most to you. Work down this list; the first factor that's decisive for you usually settles it.

If maximum average weight loss is your top priority — and you don't have a specific reason to prefer semaglutide — the head-to-head data favors Zepbound. It lost more in the only trial that compared them directly, and more in its own pivotal trial than semaglutide did in its. If you want to tilt the odds toward the biggest result, that's the tilt.

If heart-health evidence matters most to you — for example, you have cardiovascular risk factors — Wegovy has the standout data here. The SELECT trial (NEJM 2023) showed semaglutide reduced the risk of major cardiovascular events — heart attack, stroke, cardiovascular death — in people with established heart disease and obesity but without diabetes. That's a benefit beyond the number on the scale, and it's a reason a clinician might steer you to semaglutide specifically. Tirzepatide's cardiovascular-outcomes evidence is still maturing.

If you can't stand needles, the comparison tilts toward semaglutide, because it's the one with an oral pill option (the Wegovy pill); Zepbound is injection-only. If insurance covers one and not the other, that's often the whole decision — take the covered one at ~$25/month and don't overthink the trial averages. If you're paying cash and budget is tight, the real choice may not be between the two brands at all but between branded and a carefully vetted compounded program, as covered above. And if you've tried one and it didn't agree with you — side effects you couldn't manage, or weight loss that stalled at a tolerable dose — switching to the other is a normal, common move, because individual response varies unpredictably between the two.

Here's the meta-point that should sit above all of these factors: the best drug for you is heavily shaped by your own medical history, and that's a conversation for a prescriber, not a guide. Your other conditions, your medications, your heart and thyroid history, what your insurance will do, and how your body responds all feed into a decision that no article can make for you. What this guide can do is make you a well-informed participant in that conversation: you now know Zepbound tends to win on weight, Wegovy has the heart data and the pill, the side-effect profiles are broadly similar with a slight head-to-head edge to Zepbound on dropouts, and cost often decides it. Bring that to a real clinician and the choice usually becomes clear.

If you're still genuinely torn after all that, a reasonable default looks like this: get whichever your insurance covers; if neither is covered and you're paying cash, choose by priority — Zepbound for the biggest likely weight loss, Wegovy if heart-risk data or a pill option matters — and if cash brand pricing is out of reach, a vetted compounded program is the pragmatic path. None of those is a wrong answer. The wrong answer is picking by hype, rushing the dose, or buying from a program that skips the medical part to shave a few dollars.

Switching between them (and starting over)

Because the two drugs are so often framed as rivals, people assume picking one is a permanent commitment. It isn't. Switching between semaglutide and tirzepatide is common, legitimate, and sometimes the smartest move — and knowing that takes a lot of pressure off the initial choice.

There are two main reasons people switch. The first is tolerability: someone gets side effects on one drug that they can't manage even with a careful titration, switches to the other, and does fine. Because the drugs aren't identical — different molecules, tirzepatide's extra GIP action — individual guts respond to them differently in ways no one can predict in advance. A rough ride on one is not a verdict on the whole drug class; it's often just a reason to try the other. The second reason is plateau or insufficient results: someone on semaglutide who's stalled below their goal at a tolerated dose may switch to tirzepatide for its higher ceiling, or vice versa for other reasons. Either switch is a normal clinical decision, made with a prescriber, not a sign anything failed.

The mechanics matter, though, and this is firmly a clinician's call, not a DIY move. Switching isn't a simple swap at equivalent doses — the two drugs don't map onto each other one-to-one, so your prescriber will choose an appropriate starting dose on the new drug and usually re-titrate up, which means a short step back down in dose intensity while your body re-adapts. Done right, it's smooth; done wrong (jumping to a high dose on the new drug to "keep up"), it reproduces the rough first month. The same "start low, go slow" logic that governs starting governs switching.

There's also a cost-and-access angle to switching that's easy to miss. If one drug's price, coverage, or supply changes — a promotion ends, a formulary shifts, a program raises prices — switching to the other (or from branded to compounded, or compounded to branded) can be a reasonable response. The point is that you retain optionality. You are not locked in by your first choice, which is exactly why the first choice shouldn't feel high-stakes. Start with whichever makes sense on today's facts (coverage, budget, priorities), give it a real trial, and switch if the evidence of your own experience says to.

One caution: switching repeatedly or impulsively — chasing faster results by hopping drugs every few weeks — is counterproductive, because you never give either drug the stable titration it needs to show what it can do. Switching is a tool for a specific problem (intolerable side effects, a genuine plateau, a cost or access change), used deliberately with a clinician. Used that way, it's one of the quiet advantages of there being two good options instead of one.

Insurance and coverage in 2026

Coverage is the single biggest swing factor in what you'll actually pay, and it's also the most confusing, so it earns its own section. The headline: coverage for weight loss specifically remains uneven and often restrictive, but it's not nothing, and the details decide hundreds of dollars a month.

The core problem is that many health plans treat weight-loss medication differently from the same drug prescribed for a different condition. A plan might cover semaglutide for type 2 diabetes (as Ozempic) or for cardiovascular risk reduction, but exclude it for obesity (as Wegovy), even though it's the same molecule. Employer plans vary enormously: some cover weight-loss GLP-1s generously, some gate them behind a BMI threshold, documented prior attempts, or prior authorization, and some exclude them outright. The first move is always to find out what your specific plan does for each drug — because the answer frequently picks the drug for you. If your formulary covers Zepbound but not Wegovy, that's your answer, and vice versa.

When a drug is covered, the manufacturer savings cards stack on top to bring the cost down to roughly $25/month for eligible commercial-insurance patients — the cheapest route available. When it's not covered, you're into self-pay territory, where the manufacturers' direct programs (NovoCare for Wegovy, LillyDirect for Zepbound) set the brand floor, and compounded programs undercut that substantially. This is also where a good telehealth program earns its keep: the better ones have staff who work the insurance and prior-authorization process for you, which can be the difference between a covered $25 price and an uncovered $350 one.

Medicare and Medicaid are their own world. Medicare has historically not covered drugs for weight loss alone, though coverage exists when a GLP-1 is prescribed for a covered condition, and newer pathways have opened partial access — including a program bringing certain GLP-1s to around $50/month for eligible beneficiaries within a defined window (CMS program information). These rules change yearly and vary by plan and state; if you're on Medicare or Medicaid, confirm current specifics rather than relying on last year's understanding.

The practical coverage playbook, in order: (1) check your plan's formulary for both drugs by name; (2) if either is covered, pursue the savings card for ~$25/month and let coverage decide the brand; (3) if neither is covered, price both brands' self-pay direct programs for your dose; (4) if that's still too much, evaluate a vetted compounded program; and (5) use a telehealth provider that will actually fight the insurance battle for you if you're trying to get the brand covered. Coverage is tedious to work through, but it's where the biggest dollars are won or lost — far more than the Wegovy-vs-Zepbound distinction itself for most people. Our cost guide keeps the current pricing landscape up to date.

Common myths about Wegovy vs Zepbound

This comparison attracts more confident misinformation than almost any other in the weight-loss space. Here are the claims worth correcting, because believing them leads to bad decisions.

Myth: "They're basically the same drug." They're the same class and share a lot of biology, but they're different molecules with a measurable difference in results — Zepbound lost meaningfully more weight in the head-to-head trial. "Same class" is not "same outcome." On the other hand, they're similar enough that for many people either will work well, so the opposite myth — that one is a miracle and the other is useless — is equally wrong.

Myth: "More side effects means it's working better." False, and costly. Side-effect intensity is not a weight-loss gauge; plenty of people with minimal nausea lose plenty of weight, and pushing the dose to feel more side effects doesn't buy more results — it just buys more misery and more quitting. Tellingly, in the head-to-head trial the more effective drug (Zepbound) had fewer people quit over side effects. Effectiveness and side effects are related but not the same lever.

Myth: "The new high-dose Wegovy definitely beats Zepbound now." Overclaiming. The 7.2 mg Wegovy dose does push semaglutide's results higher and narrows the gap — but it was never tested head-to-head against Zepbound, so claiming it ties or wins goes beyond the evidence. The honest statement is that it makes Wegovy a stronger contender than the 13.7% head-to-head figure suggests, not that it has overtaken tirzepatide.

Myth: "Compounded is the same as the brand, just cheaper." Same molecule, different regulatory reality. Compounded versions aren't FDA-approved and their quality depends on the pharmacy, not the agency — which can be fine with a careful, licensed provider and risky with a careless one. "Same active ingredient" is true; "therefore identical and equally safe" doesn't follow.

Myth: "You take it for a few months, lose the weight, and you're done." The hardest myth to let go of. These treat a chronic condition; stopping tends to bring weight back, as the withdrawal data shows. Whichever drug you choose, the realistic plan is long-term, which is exactly why cost, tolerability, and sustainability matter as much as the trial average. Our guide on stopping a GLP-1 covers the regain data honestly.

Myth: "The one with the bigger trial number is the one I'll lose the most on." Trial numbers are averages with huge individual spread. Your result depends on biology, dose, titration, and adherence far more than on the brand's headline percentage. Tilt the odds with the evidence, yes — but expect a personal range, not the brochure number.

What's coming next (and why it matters for your choice today)

The GLP-1 field is moving faster than almost any area of medicine, and a few developments on the near horizon are worth knowing about before you commit — not because you should wait (the drugs available now work), but because they affect how you think about flexibility and cost.

The pills are arriving. For years these drugs meant injections; that's changing. Semaglutide now has an oral form — the Wegovy pill (a 25 mg tablet) — supported by its own trial program (the OASIS studies; see OASIS 4, NEJM 2025). And a genuinely new kind of pill has arrived from the tirzepatide maker's side of the field: orforglipron, an oral small-molecule GLP-1, approved as Foundayo (Eli Lilly, 2026) with its own trial support (the ATTAIN program; ATTAIN-1, NEJM 2025). These matter to the Wegovy-vs-Zepbound decision because they expand the needle-free options and will, over time, reshape pricing as more products compete. Our weight-loss pill guide covers how the pills stack up against the injections.

Higher and more flexible dosing. The 2026 approval of the 7.2 mg high-dose Wegovy is part of a broader trend toward giving each drug a wider dose range, which means more room to push for additional weight loss (at the cost of more side effects) and more room to find a tolerable maintenance level. Expect the "ceiling" on both molecules to keep evolving, which is one more reason today's head-to-head average is a snapshot, not a permanent verdict.

Even stronger agents are in trials. Beyond semaglutide and tirzepatide, next-generation molecules targeting additional hormone pathways have posted striking weight-loss numbers in earlier-stage research. They aren't approved for general use yet and shouldn't factor into a decision you're making now, but they signal the direction: more options, higher ceilings, and — eventually — more price competition. The practical implication is don't over-agonize over a permanent choice. You're not marrying a molecule. The field will offer more routes over the next few years, switching is normal, and the right move is to start effective treatment now with whichever drug fits your coverage, budget, and medical picture — not to wait for a perfect future option while carrying the health costs of obesity in the meantime.

One caution about the pipeline hype: emerging trial numbers are reported under ideal conditions and often shrink in real-world use, and "approved" is a very different thing from "in a late-stage trial." Treat anything that isn't FDA-approved and available as interesting context, not a reason to delay. The two drugs this guide compares are proven, available, and effective today; the pipeline is a reason for optimism about the future, not a reason to postpone the present.

Wegovy vs Zepbound: frequently asked questions

Is Zepbound better than Wegovy for weight loss?

On average, yes — in the only head-to-head trial (SURMOUNT-5), Zepbound (tirzepatide) produced more weight loss than Wegovy (semaglutide): about 20.2% versus 13.7% of body weight over 72 weeks, and with fewer people stopping over side effects. But "better on average" isn't "better for everyone." Wegovy has standout cardiovascular-outcome data, an oral pill option, a longer track record, and a new higher 7.2 mg dose that narrows the weight-loss gap. For many people the deciding factor ends up being insurance coverage, cost, side-effect tolerance, or a clinician's read of their medical history — not the trial average.

How much weight will I lose on each?

Expect a range, not a guarantee. In the trials, Wegovy averaged around 14.9% of body weight (STEP 1) and Zepbound around 21% at the top dose (SURMOUNT-1), with the head-to-head showing 13.7% vs 20.2%. But individual results spanned from almost nothing to 30%+, driven by biology, dose, titration, and how long you stay on. The averages tilt toward Zepbound; your personal result depends on far more than the brand.

Which has fewer side effects?

The profiles are broadly similar — both are mostly gastrointestinal (nausea, constipation, diarrhea), worst at the start and each dose increase, then fading. In the head-to-head trial, fewer people actually stopped Zepbound over side effects (about 2.7% vs 5.6%), which cuts against the idea that the stronger drug is rougher. But tolerance is individual: some people do better on one than the other, and careful titration matters more than the brand.

Can I switch from Wegovy to Zepbound or vice versa?

Yes, and it's common. People switch for side effects they can't manage or for a plateau, and because individual response varies unpredictably, someone who struggles on one often does well on the other. It's a clinician's decision, not a DIY swap — the drugs don't map one-to-one, so your prescriber will set an appropriate starting dose on the new drug and re-titrate up.

Is compounded semaglutide or tirzepatide as good as Wegovy or Zepbound?

It's the same active molecule but not the same product: compounded versions aren't FDA-approved, so quality depends on the compounding pharmacy rather than the agency's review. Many licensed programs do it carefully and at a fraction of the brand price, which is why a lot of cash-paying people choose it. The trade-off is real — you give up FDA approval and manufacturer quality control for the lower cost — so vetting the provider matters more than with the brand. If you can get the brand covered by insurance for around $25/month, that's usually the better deal.

What does each cost in 2026?

With commercial insurance that covers the drug, a manufacturer savings card can bring either to roughly $25/month. Paying cash for the brand directly, Wegovy runs around $349/month (with lower intro pricing on early fills) and Zepbound roughly $299–$499/month by dose. Compounded alternatives from online programs often run about $49–$199/month but aren't FDA-approved. All of these change often — verify the current number for your dose before deciding.

Can I get Wegovy or Zepbound online?

Yes. Legitimate telehealth programs can do a proper medical intake, connect you with a licensed clinician, prescribe the branded drug, and help with insurance and savings cards; others sell lower-cost compounded alternatives. The non-negotiables are a real medical intake (not just a payment form), a licensed prescriber, transparent ongoing pricing, and clear refill and cancellation terms. See our provider reviews and the guide on spotting a legit online clinic.

Does the new higher-dose Wegovy (7.2 mg) beat Zepbound?

Not proven. The 7.2 mg dose, approved in 2026, pushes semaglutide's average weight loss up toward the high-teens-to-~20% range, narrowing the gap with Zepbound — but it was never tested head-to-head against tirzepatide, so no one can honestly claim it ties or wins. It makes Wegovy a stronger contender than the standard-dose head-to-head figure suggests, at the cost of more side effects at the top dose.

Quick glossary

Semaglutide — the molecule in Wegovy (weight loss) and Ozempic (diabetes); a single-hormone GLP-1 receptor agonist. Tirzepatide — the molecule in Zepbound (weight loss) and Mounjaro (diabetes); a dual GLP-1/GIP agonist. GLP-1 / GIP — gut hormones the drugs mimic to reduce appetite and slow stomach emptying; tirzepatide hits both, semaglutide hits one. Titration — the gradual dose step-up over months that keeps side effects tolerable. Compounded — a drug mixed by a pharmacy rather than manufactured and FDA-approved as a finished product; same molecule, different regulatory status. Maintenance dose — the ongoing effective dose you reach after titrating up. Head-to-head trial — a study giving the same population one drug or the other and comparing directly (here, SURMOUNT-5).

The honest verdict

Put it all together and the picture is clear without being simplistic. Zepbound wins the weight-loss contest — it lost more in the only trial that compared them directly, and more in its own pivotal trial, with fewer people quitting over side effects. If maximum likely weight loss is your single priority and nothing else overrides it, that's the tilt. Wegovy is the proven all-rounder — the longer track record, the landmark heart-outcome data, an oral pill option, and a new higher dose that narrows the weight-loss gap — and for people with cardiovascular risk, a needle aversion, or a formulary that prefers it, it's often the better personal choice despite the lower head-to-head number.

But the honest meta-verdict is that for most people, the decision is made by cost, coverage, and sustainability more than by the trial average. The best drug is the one you can get covered or afford, tolerate well enough to stay on, and keep taking long enough to matter — because stopping brings the weight back whichever brand you chose. Take whichever your insurance covers; if you're paying cash, choose by your priority and consider a vetted compounded alternative if brand pricing is out of reach; give it a real titration and several months; and do all of it with a genuine prescriber rather than a checkout questionnaire. Get those fundamentals right and either of these drugs can change your health. Get them wrong — picking by hype, rushing the dose, or buying from a program that skips the medicine — and the best molecule in the world won't save a bad plan.

When you're ready to act on this, compare the programs that prescribe these drugs — branded and compounded — in our ranked comparison, read the individual provider reviews, and browse the head-to-head matchups. And remember the one line that matters more than Wegovy vs Zepbound: do this with a real clinician who takes a real history. That single choice protects you more than picking the "right" brand ever will.